Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP +13.98%89 Cash-to-Debt is 0.19 as of Mar. 2026, which is at its 10-year median of 0.19. GuruFocus rates ASX:AFP with a GF Score™ of 89/100 and a GF Value™ of A$3.41 (Fairly Valued). The stock has 5 warning signs investors should review. Among 986 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 78.5% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AFT Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.19.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, AFT Pharmaceuticalscouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for AFT Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
ASX:AFP'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.19 Max: 0.68
Current: 0.19
During the past 11 years, AFT Pharmaceuticals's highest Cash to Debt Ratio was 0.68. The lowest was 0.08. And the median was 0.19.
ASX:AFP's Cash-to-Debt is ranked worse than 78.5% of 986
companies
in the Drug Manufacturers industry
Industry Median: 1.01
vs ASX:AFP: 0.19
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
AFT Pharmaceuticals Cash-to-Debt Related Terms
AFT Pharmaceuticals Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:AFP vs ZTS, UTHR, VTRS: Cash-to-Debt Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals (ASX:AFP) has a Cash-to-Debt of 0.19 as of Mar. 2026. This is near median its historical median of 0.19. Over the past decade, AFT Pharmaceuticals' Cash-to-Debt has ranged from 0.08 to 0.68. According to the industry distribution chart, AFT Pharmaceuticals ranks #774 out of 986 companies in the Drug Manufacturers industry, placing it in the top 78.5%.
Is AFT Pharmaceuticals' Cash-to-Debt too high?
AFT Pharmaceuticals' current Cash-to-Debt of 0.19 is near median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.68. The Drug Manufacturers industry median Cash-to-Debt is 1.01. AFT Pharmaceuticals' value of 0.19 is 81.2% below this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #774 out of 986 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AFT Pharmaceuticals has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #774 out of 986 companies for Cash-to-Debt. This places AFT Pharmaceuticals in the lower half of its industry. The industry median Cash-to-Debt is 1.01. AFT Pharmaceuticals' value of 0.19 is 81.2% below this benchmark. Historically, AFT Pharmaceuticals' own Cash-to-Debt has ranged from 0.08 to 0.68 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 1.01, AFT Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 1.01, based on 986 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Cash-to-Debt of 0.19 is 81.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 1.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Cash-to-Debt is 0.19, which is near median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.41, compared to a current price of A$3.75 — trading 10% above its estimated fair value. The current Cash-to-Debt is 0.19, which is near median its 10-year median of 0.19 and 81.2% below the Drug Manufacturers industry median of 1.01. AFT Pharmaceuticals' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Cash-to-Debt is 0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be overvalued.
The current stock price of A$3.75 is trading 10% above its estimated GF Value™ of A$3.41.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for ASX:AFP:
Cash-to-Debt: 0.19 (near median its 10-year median of 0.19)
GF Value™: A$3.41 vs. price of A$3.75 (10% above fair value)
Industry Position: 81.2% below the Drug Manufacturers median (#774 of 986)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
89GF Score
Get the complete analysis for ASX:AFP
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
